Proteins



XYD190

Molecular Weight:

Cat. No.: HY-161494

Molecular Formula: $C_{55}H_{50}F_2N_{10}O_7$


PROTACs; Epigenetic Reader Domain Target:

1001.05

Pathway: PROTAC; Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



Product Data Sheet

BIOLOGICAL ACTIVITY

Description

XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC $_{50}$ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496))^[1].

In Vitro

 $XYD190 \ (0-1 \ \mu\text{M}, 72-120 \ h) \ inhibits \ proliferations \ of acute \ myeloid \ leukemia \ (AML) \ cells \ MV4; 11, MOLM-13 \ and \ MOLM-16, with \ models \$ the IC_{50} of 1.8, 26.9 and 4.6 nM, respectively^[1].

XYD190 (0-150 nM, 6 h) induces CBP and p300 degradation in bromodomain family proteins in a CRBN- and proteasomedependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation $Assay^{[1]}$

Cell Line:	MV4;11 AML, MOLM-13 and MOLM-16
Concentration:	0-1 μΜ
Incubation Time:	3 days for MOLM-13, 4 days for MV4;11 AML and MOLM-16
Result:	Inhibited cell proliferation.

Western Blot Analysis^[1]

Cell Line:	MV4;11 AML, MOLM-13 and MOLM-16
Concentration:	0-150 nM
Incubation Time:	6 h
Result:	Degraded CBP and p300 proteins.

In Vivo

CBP/p300 ligand 4 (5 mg/kg, p.o., every other day for 2 weeks) exhibits antitumor activity in MV4;11 xenograft mice model, with a tumor growth inhibition rate TGI of 88%^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MV4;11 xenograft NOD-SCID mice model $^{[1]}$
Dosage:	5 mg/kg
Administration:	p.o., every other day for 2 weeks
Result:	Inhibited tumor growth with a TGI of 88%.

REFERENCES

[1]. Hu J, et al., Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. J Med Chem. 2024 May 9;67(9):6952-6986.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com